|Mr. Mark Timney||CEO & Director||86.54k||N/A||1965|
|Mr. Christopher J. Visioli||CFO & Treasurer||528.05k||N/A||1976|
|Mr. Stephen M. Rodin J.D.||Exec. VP, Gen. Counsel & Sec.||657.05k||N/A||1976|
|Dr. Clive A. Meanwell||Chief Innovation Officer & Director||1.21M||N/A||1958|
|Dr. Goutham Krishna Gorti||VP & Head of Investor Relations||N/A||N/A||N/A|
The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc. The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey.
The Medicines Company’s ISS Governance QualityScore as of October 4, 2019 is 4. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 4; Compensation: 9.